Skip to main content
SpringerLink
Log in

Depot Medroxyprogesterone Acetate

  • Chapter
  • First Online:
The Handbook of Contraception

Part of the book series: Current Clinical Practice ((CCP))

  • 796 Accesses

Abstract

Depot medroxyprogesterone acetate (DMPA) is an injectable progestin-only contraceptive administered every 13 weeks. DMPA is an extremely effective contraceptive agent when used consistently. With typical use, approximately 6 out of 100 women will become pregnant in the first year of use, reflecting that some users do not return for repeat injections. DMPA is reversible and can be used by women of all ages; however, there is a delayed return to fertility after discontinuation (median duration 10 months). There are few contraindications to DMPA use and it can be used in postpartum and breastfeeding women. Noncontraceptive benefits of DMPA include treatment of heavy menstrual bleeding, dysmenorrhea, endometriosis, and a decreased risk of endometrial and ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention: U.S. Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd edition. Morbidity and Mortality Weekly Report: Recommendations and Reports. 2013;62:1–60.

    Google Scholar 

  2. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.

    PubMed  PubMed Central  Google Scholar 

  3. Curtis KM, Tepper NK, Jatlaoui TC, et al. U S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3):1–103.

    PubMed  Google Scholar 

  4. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1996;41:381–90.

    CAS  PubMed  Google Scholar 

  5. Paulen ME, Curtis KM. When can a woman have repeat progestogen-only injectables--depot medroxyprogesterone acetate or norethisterone enantate? Contraception. 2009;80(4):391–408.

    CAS  PubMed  Google Scholar 

  6. Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7–17.

    CAS  PubMed  Google Scholar 

  7. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28(1):1–20.

    Google Scholar 

  8. Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85(2):314–25.

    CAS  PubMed  Google Scholar 

  9. Mishell DR Jr, Kharma KM, Thorneycroft IH, et al. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol. 1972;113(3):372–6.

    PubMed  Google Scholar 

  10. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception. 2002;65(1):21–7.

    CAS  PubMed  Google Scholar 

  11. Westhoff C. Depot-medroxyprogesterone acetate injection (depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68(2):75–87.

    CAS  PubMed  Google Scholar 

  12. Manchikanti A, Grimes DA, Lopez LM, et al. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007;2:CD006261.

    Google Scholar 

  13. Dutton C, Foldvary-Schaefer N. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management. Int Rev Neurobiol. 2008;83:113–34.

    PubMed  Google Scholar 

  14. Hubacher D, Lopez L, Steiner MJ, et al. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception. 2009;80(2):113–8.

    CAS  PubMed  Google Scholar 

  15. ACOG Practice Bulletin No. 110. Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010;115:206–18.

    Google Scholar 

  16. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Cancer 1991;49(2):186-190.

    Google Scholar 

  17. Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119:672–7.

    CAS  PubMed  Google Scholar 

  18. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.

    PubMed  PubMed Central  Google Scholar 

  19. Hubacher D, Goco N, Gonzalez B, et al. Factors affecting continuation rates of DMPA. Contraception. 1999;60(6):345–51.

    CAS  PubMed  Google Scholar 

  20. Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;8:CD008815.

    Google Scholar 

  21. Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56.

    CAS  PubMed  Google Scholar 

  22. Vickery Z, Madden T, Zhao Q, et al. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88(4):503–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Westhoff C, Wieland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception. 1995;51(6):351–4.

    CAS  PubMed  Google Scholar 

  24. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10(2):181–202.

    CAS  PubMed  Google Scholar 

  25. ACOG Practice Bulletin No. 206. Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):e128–50.

    Google Scholar 

  26. Braga GC, Ferriolli E, Quintana SM, et al. Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact. Contraception. 2015;92(6):536–42.

    CAS  PubMed  Google Scholar 

  27. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2016;94(3):226–52.

    CAS  PubMed  Google Scholar 

  28. World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1–164.

    Google Scholar 

  29. Pfizer. Letter to health care professionals. 2004. Available at: http://www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166395.pdf. Retrieved October 18, 2013.

  30. ACOG Committee Opinion No. 602. Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123(6):1398–402.

    Google Scholar 

  31. Centers for Disease Control and Prevention: U.S. Selected Practice Recommendations for Contraceptive Use, 2016. Morbidity and Mortality Weekly Report: Recommendations and Reports. 2016;65(4):1–66.

    Google Scholar 

  32. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int. 2001;12(10):828–34.

    CAS  PubMed  Google Scholar 

  33. Sowers M, Corton G, Shapiro B, et al. Changes in bone density with lactation. JAMA. 1993;269(24):3130–5.

    CAS  PubMed  Google Scholar 

  34. Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25–35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74(2):90–9.

    CAS  PubMed  Google Scholar 

  35. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77(2):67–76.

    CAS  PubMed  Google Scholar 

  36. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81(4):281–91.

    CAS  PubMed  Google Scholar 

  37. Dragoman M, Kaunitz AM, McClung M. Bone health and hormonal contraception. In: Allen RH, Cwiak CA, editors. Contraception for the medically challenging patient: Springer; 2014.

    Google Scholar 

  38. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95(11):4909–16.

    CAS  PubMed  Google Scholar 

  39. Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121(3):593–600.

    CAS  PubMed  Google Scholar 

  40. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008;78(6):459–64.

    CAS  PubMed  Google Scholar 

  41. Kaunitz AM, Peipert JF, Grimes DA. Injectable contraception: issues and opportunities. Contraception. 2014;89(5):331–4.

    PubMed  Google Scholar 

  42. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents -- the black box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39(2):296–301.

    PubMed  Google Scholar 

  43. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001;185(2):380–5.

    CAS  PubMed  Google Scholar 

  44. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12(1):e1001778.

    PubMed  PubMed Central  Google Scholar 

  45. Ralph LJ, McCoy SI, Shiu K, et al. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181–9.

    PubMed  PubMed Central  Google Scholar 

  46. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2(10):1084–9.

    CAS  PubMed  Google Scholar 

  47. Vishwanathan SA, Guenthner PC, Lin CY, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr. 2011;57(4):261–4.

    CAS  PubMed  Google Scholar 

  48. Miller L, Patton DL, Meier A, et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96(3):431–9.

    CAS  PubMed  Google Scholar 

  49. Bahamondes MV, Castro S, Marchi NM, et al. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Contraception. 2014;90(2):117–22.

    CAS  PubMed  Google Scholar 

  50. Michel KG, Huijibregts RPH, Richter HE, et al. Effect of depot medroxyprogesterone acetate on human β-defensin production and structural integrity of the human vaginal epithelium. Lancet. 2013;382(supp 2):S1–S25.

    Google Scholar 

  51. Hapgood JP, Kaushic C, Hel Z. Hormonal contraception and HIV-1 acquisition: biological mechanisms. Endocrine review. 2018;39(1):36–78.

    Google Scholar 

  52. World Health Organization. Guidance Statement: Hormonal contraceptive methods for women at high risk of HIV and living with HIV. 2017. Available at https://apps.who.int/iris/bitstream/handle/10665/128537/WHO_RHR_14.24_eng.pdf;jsessionid=346C9F1D8947E6820FA8710624E3ED2F?sequence=1

  53. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13.

    Google Scholar 

  54. Overton ET, Shacham E, Singhatiraj E, et al. Incidence of sexually transmitted infections among HIV-infected women using depot medroxyprogesterone acetate contraception. Contraception. 2008;78(2):125–30.

    CAS  PubMed  Google Scholar 

  55. Tepper NK, Jeng G, Curtis KM, et al. Venous thromboembolism among women initiating depot medroxyprogesterone acetate immediately postpartum. Obstet Gynecol. 2019;133(3):533–40.

    CAS  PubMed  Google Scholar 

  56. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Cancer. 1991;49(2):186–90.

    Google Scholar 

  57. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Contraception. 1992;45(4):299–312.

    Google Scholar 

  58. Li CI, Beaber EF, Tang MT, et al. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res. 2012;72(8):2028–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187–98.

    PubMed  Google Scholar 

  60. Skegg DC, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA. 1995;273(101):799–804.

    CAS  PubMed  Google Scholar 

  61. Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics. 1994;94(5):687–94.

    CAS  PubMed  Google Scholar 

  62. Newton JR, d’Arcangues C, Hall PE. A review of “once-a-month” combined injectable contraceptives. J Obstet Gynaecol. 1994;14(Suppl 1):1–34.

    Google Scholar 

  63. Tyler ET, Levin M, Elliot J, Dolman H. Present status of injectable contraceptives: results of seven-years study. Fertil Steril. 1970;21:469–81.

    CAS  PubMed  Google Scholar 

  64. Jain J, Jakimuik AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269.

    CAS  PubMed  Google Scholar 

  65. Canto De Cetina TE, Canto P, Ordoñez Luna M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception. 2001;63(3):143–6.

    CAS  PubMed  Google Scholar 

  66. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception. 1996;53(6):357–61.

    CAS  PubMed  Google Scholar 

  67. Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA, Fetih GN. Doxycycline in the treatment of bleeding with DMPA: a double-blinded randomized controlled trial. Contraception. 2012;86:224.

    CAS  PubMed  Google Scholar 

  68. Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular bleeding in DMPA users. Contraception. 2004;70(4):277–9.

    CAS  PubMed  Google Scholar 

  69. Senthong AJ, Taneepanichskuk S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thail. 2009;92(4):461–5.

    Google Scholar 

  70. Edelman A, Kaneshiro B. Management of unscheduled bleeding in women using contraception. UpToDate. Retrieved March 21, 2019.

    Google Scholar 

  71. Jain JK, Nicosia AF, Nucatola DL, et al. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids. 2003;68(10-13):1115–9.

    CAS  PubMed  Google Scholar 

  72. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43–52.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA

    Deanna C. McCullough, Kathryn M. Eraso & Andrew M. Kaunitz

Authors
  1. Deanna C. McCullough
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn M. Eraso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew M. Kaunitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deanna C. McCullough .

Editor information

Editors and Affiliations

  1. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Donna Shoupe

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

McCullough, D.C., Eraso, K.M., Kaunitz, A.M. (2020). Depot Medroxyprogesterone Acetate. In: Shoupe, D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana, Cham. https://doi.org/10.1007/978-3-030-46391-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-46391-5_6

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-46390-8

  • Online ISBN: 978-3-030-46391-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation